These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 21278224)

  • 21. First-Line and Sequential Use of Pazopanib Followed by Mammalian Target of Rapamycin Inhibitor Therapy Among Patients With Advanced Renal Cell Carcinoma in a US Community Oncology Setting.
    Vogelzang NJ; Hackshaw MD; Hutson TE; Bhowmik D; Yap M; Rembert D; Jonasch E
    Clin Genitourin Cancer; 2015 Jun; 13(3):210-7. PubMed ID: 25498215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B; Coskun U; Yildiz R; Buyukberber S; Baykara M; Benekli M
    J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adverse events associated with mTOR inhibitors.
    Pallet N; Legendre C
    Expert Opin Drug Saf; 2013 Mar; 12(2):177-86. PubMed ID: 23252795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience.
    Errasti P; Izquierdo D; Martín P; Errasti M; Slon F; Romero A; Lavilla FJ
    Transplant Proc; 2010 Oct; 42(8):3053-4. PubMed ID: 20970608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapy of sclerodermatous chronic graft-versus-host disease with mammalian target of rapamycin inhibitors.
    Jedlickova Z; Burlakova I; Bug G; Baurmann H; Schwerdtfeger R; Schleuning M
    Biol Blood Marrow Transplant; 2011 May; 17(5):657-63. PubMed ID: 20696263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
    Huang Z; Wu Y; Zhou X; Qian J; Zhu W; Shu Y; Liu P
    Future Oncol; 2015; 11(11):1687-99. PubMed ID: 26043220
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteinuria associated with mTOR inhibitors after kidney transplant.
    Guney M; Sahin G; Yilmaz B; Canbakan M; Gucun M; Kayatas K; Eren P; Titiz I
    Exp Clin Transplant; 2014 Dec; 12(6):539-42. PubMed ID: 25489805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Everolimus for the treatment of advanced renal cell carcinoma.
    Amato R
    Expert Opin Pharmacother; 2011 May; 12(7):1143-55. PubMed ID: 21470068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interstitial pneumonitis as an adverse reaction to mTOR inhibitors.
    Molas-Ferrer G; Soy-Muner D; Anglada-Martínez H; Riu-Viladoms G; Estefanell-Tejero A; Ribas-Sala J
    Nefrologia; 2013; 33(3):297-300. PubMed ID: 23712219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Everolimus.
    Hasskarl J
    Recent Results Cancer Res; 2014; 201():373-92. PubMed ID: 24756805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. mTOR Inhibition and Clinical Transplantation: Kidney.
    Flechner SM
    Transplantation; 2018 Feb; 102(2S Suppl 1):S17-S18. PubMed ID: 28230636
    [No Abstract]   [Full Text] [Related]  

  • 33. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
    Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
    Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mTOR, glycotoxins and the parallel universe.
    Green AS
    Aging (Albany NY); 2018 Dec; 10(12):3654-3656. PubMed ID: 30540565
    [No Abstract]   [Full Text] [Related]  

  • 35. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids.
    Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC
    Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Braun WE
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
    [No Abstract]   [Full Text] [Related]  

  • 37. [Hyperglycaemia during treatment with everolimus].
    Opdam FL; Huitema AD; Beijnen JH; Schellens JH
    Ned Tijdschr Geneeskd; 2014; 158():A7544. PubMed ID: 25115206
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Everolimus- and temsirolimus-associated enteritis: report of three cases.
    Parithivel K; Ramaiya N; Jagannathan JP; O'Regan K; Krajewski K; Fisher D; Choueiri TK; Jacobsen E
    J Clin Oncol; 2011 May; 29(14):e404-6. PubMed ID: 21357780
    [No Abstract]   [Full Text] [Related]  

  • 39. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Grantham JJ; Bennett WM; Perrone RD
    N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
    [No Abstract]   [Full Text] [Related]  

  • 40. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Levey AS; Stevens LA
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.